Sana Biotechnology (SANA) Total Current Liabilities (2020 - 2026)

Sana Biotechnology has reported Total Current Liabilities for 7 years, with the latest figure at $86.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 160.18% year-over-year to $86.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.3 million (up 160.18% YoY) and the FY2025 annual result came in at $78.7 million, up 73.28% from the prior year.
• Total Current Liabilities improved to $86.3 million in Q1 2026 per SANA's latest filing, from $78.7 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $114.8 million in Q3 2022 and troughed at $33.2 million in Q1 2025.
• A 5-year average of $72.1 million and a median of $66.6 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 166.03% in 2022, then slumped 54.78% in 2024.
• Over 5 years, Total Current Liabilities stood at $111.5 million in 2022, then slumped by 42.17% to $64.5 million in 2023, then slipped by 29.55% to $45.4 million in 2024, then soared by 73.28% to $78.7 million in 2025, then grew by 9.58% to $86.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $86.3 million, $78.7 million, and $35.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.